Oct 05, 2020 / 06:30PM GMT
Biren N. Amin - Jefferies LLC, Research Division - MD and Senior Equity Research Analyst
Welcome, everyone, to the Jefferies Cell Therapy Summit. I'd like to welcome our next company. We have Adicet Bio, their CEO, Chen Schor; and their Chief Scientific Officer, Stewart Abbot. So welcome guys. We've got about 25 minutes. This is going to be a fireside chat format. (Operator Instructions).
Just for those that aren't familiar with Adicet, recently became public through a reverse merger. Maybe, Chen, just talk about high-level pipeline, objective in cell therapy, what you're hoping to accomplish and then we can go into specific programs.
Chen Schor - Adicet Bio, Inc. - CEO, President & Director
Absolutely. So first of all, Biren, thank you so much for inviting us. I mean, it's especially great to be here with your expertise in the field of cell therapy. So perhaps I'll give a brief background about gamma delta T cells and brief about the pipeline.
So yes -- gamma delta T cells, the first important piece of evidence actually comes from an
Adicet Bio Inc at Jefferies Cell Therapy Summit Transcript
Oct 05, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers